-+ 0.00%
-+ 0.00%
-+ 0.00%

Zentalis Pharmaceuticals launches underwritten public offering of common stock, pre-funded warrants

PUBT·08/13/2026 20:02:26
Listen to the news
Zentalis Pharmaceuticals launches underwritten public offering of common stock, pre-funded warrants
  • Zentalis launched a proposed underwritten public offering of common stock.
  • Some investors can choose pre-funded warrants to buy common shares in lieu of stock.
  • Underwriters hold a 30-day option to purchase up to 15% additional shares on the same terms.
  • Proceeds earmarked for clinical trials, preclinical work, regulatory filings, manufacturing, companion diagnostic development, pre-commercial activities, capital spending, working capital.
  • TD Cowen, Guggenheim Securities, Oppenheimer are joint bookrunners.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131601PRIMZONEFULLFEED9809901) on August 13, 2026, and is solely responsible for the information contained therein.